Our Pipeline

At Servier Pharmaceuticals, our core business is focused in oncology where we believe that we have a unique opportunity to redefine how cancer is treated. We are committed to finding solutions that will address today's challenges. We aim to understand the needs of our patients at all points of their journey, while ensuring those who can benefit from our products have access to them. Advancing innovation for patients is at the heart of everything we do. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to deliver significant advances in areas of high unmet need that may truly move the needle for our patients. 

Servier’s pipeline includes many oncology assets at varying stages of clinical development.

Hematological Malignancies

Molecule Area Primary Indication Partner Territory Phase

Ivosidenib + 7+3 (chemo)

Hematological malignancies (new indication)
Worldwide
Phase 3
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
CStone Pharmaceuticals
PARTNER
Worldwide
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
CStone Pharmaceuticals
TERRITORY
Worldwide
Hematological malignancies (new indication)
CStone Pharmaceuticals
Worldwide

UCART 19

Hematological malignancies
Worldwide ex-US
Phase 2
PRIMARY INDICATION
Hematological malignancies
PARTNER
Cellectis, Allogene
PARTNER
Worldwide ex-US
PRIMARY INDICATION
Hematological malignancies
PARTNER
Cellectis, Allogene
TERRITORY
Worldwide ex-US
Hematological malignancies
Cellectis, Allogene
Worldwide ex-US

Calaspargase pegol

Hematological malignancies (new indication)
Worldwide
Phase 2
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
TERRITORY
Worldwide
Hematological malignancies (new indication)
Worldwide

Pegaspargase

Hematological malignancies (new indication)
Worldwide
Phase 2
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
TERRITORY
Worldwide
Hematological malignancies (new indication)
Worldwide

Ivosidenib

Hematological malignancies (new indication)
Worldwide
Phase 2
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
CStone Pharmaceuticals
PARTNER
Worldwide
PRIMARY INDICATION
Hematological malignancies (new indication)
PARTNER
CStone Pharmaceuticals
TERRITORY
Worldwide
Hematological malignancies (new indication)
CStone Pharmaceuticals
Worldwide

BCL-2 inhibitor + Mcl1 inhibitor (S64315)

Acute Myeloid Leukemia
Worldwide ex-US/CAN, JAP, some EU countries
Phase 2
PRIMARY INDICATION
Acute Myeloid Leukemia
PARTNER
Novartis, Vernalis
PARTNER
Worldwide ex-US/CAN, JAP, some EU countries
PRIMARY INDICATION
Acute Myeloid Leukemia
PARTNER
Novartis, Vernalis
TERRITORY
Worldwide ex-US/CAN, JAP, some EU countries
Acute Myeloid Leukemia
Novartis, Vernalis
Worldwide ex-US/CAN, JAP, some EU countries

BCL-2 inhibitor + azacitidine

1st line Acute Myeloid Leukemia (AML)
Worldwide ex-US/CAN, JAP, some EU countries
Phase 2
PRIMARY INDICATION
1st line Acute Myeloid Leukemia (AML)
PARTNER
Novartis, Vernalis
PARTNER
Worldwide ex-US/CAN, JAP, some EU countries
PRIMARY INDICATION
1st line Acute Myeloid Leukemia (AML)
PARTNER
Novartis, Vernalis
TERRITORY
Worldwide ex-US/CAN, JAP, some EU countries
1st line Acute Myeloid Leukemia (AML)
Novartis, Vernalis
Worldwide ex-US/CAN, JAP, some EU countries

Solid Tumors

Molecule Area Primary Indication Partner Territory Phase

FTD/TPI combo bevacizumab

Solid tumors (new indication)
Worldwide ex-US/CAN, MEX & Asia
Phase 3
PRIMARY INDICATION
Solid tumors (new indication)
PARTNER
Taiho Oncology
PARTNER
Worldwide ex-US/CAN, MEX & Asia
PRIMARY INDICATION
Solid tumors (new indication)
PARTNER
Taiho Oncology
TERRITORY
Worldwide ex-US/CAN, MEX & Asia
Solid tumors (new indication)
Taiho Oncology
Worldwide ex-US/CAN, MEX & Asia

Futuximab / modotuximab combo FTD/TPI

Solid tumors (new indication)
Worldwide ex-US/CAN, MEX & Asia
Phase 3
PRIMARY INDICATION
Solid tumors (new indication)
PARTNER
PARTNER
Worldwide ex-US/CAN, MEX & Asia
PRIMARY INDICATION
Solid tumors (new indication)
PARTNER
TERRITORY
Worldwide ex-US/CAN, MEX & Asia
Solid tumors (new indication)
Worldwide ex-US/CAN, MEX & Asia

Vorasidenib

Low grade Glioma with IDH 1/2 mutation
Worldwide
Phase 3
PRIMARY INDICATION
Low grade Glioma with IDH 1/2 mutation
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Low grade Glioma with IDH 1/2 mutation
PARTNER
TERRITORY
Worldwide
Low grade Glioma with IDH 1/2 mutation
Worldwide

Anti-MET

Non small Cell Lung Cancer
Worldwide
Phase 2
PRIMARY INDICATION
Non small Cell Lung Cancer
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Non small Cell Lung Cancer
PARTNER
TERRITORY
Worldwide
Non small Cell Lung Cancer
Worldwide

Vorasidenib + pembrolizumab

Grade 2-3 glioma with IDH1/2 mutation
Worldwide
Phase 2
PRIMARY INDICATION
Grade 2-3 glioma with IDH1/2 mutation
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Grade 2-3 glioma with IDH1/2 mutation
PARTNER
TERRITORY
Worldwide
Grade 2-3 glioma with IDH1/2 mutation
Worldwide

Ivosidenib combo

Solid tumors (new indication)
CStone Pharmaceuticals
Worldwide
Phase 2
PRIMARY INDICATION
Solid tumors (new indication)
PARTNER
Solid tumors (new indication)
PARTNER
Worldwide
PRIMARY INDICATION
Solid tumors (new indication)
PARTNER
Solid tumors (new indication)
TERRITORY
Worldwide
Solid tumors (new indication)
Solid tumors (new indication)
Worldwide

Anti-TIM3 combo

Solid tumors
Worldwide
Phase 2
PRIMARY INDICATION
Solid tumors
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Solid tumors
PARTNER
TERRITORY
Worldwide
Solid tumors
Worldwide

Anti-CD73

Solid tumors
Worldwide
Phase 2
PRIMARY INDICATION
Solid tumors
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Solid tumors
PARTNER
TERRITORY
Worldwide
Solid tumors
Worldwide

Anti-PD-L1/4-1BB

Solid Tumors
Worldwide ex-US
Phase 2
PRIMARY INDICATION
Solid Tumors
PARTNER
Pieris Pharmaceuticals
PARTNER
Worldwide ex-US
PRIMARY INDICATION
Solid Tumors
PARTNER
Pieris Pharmaceuticals
TERRITORY
Worldwide ex-US
Solid Tumors
Pieris Pharmaceuticals
Worldwide ex-US

Anti-NKG2A

Solid tumors
Worldwide
Phase 2
PRIMARY INDICATION
Solid tumors
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Solid tumors
PARTNER
TERRITORY
Worldwide
Solid tumors
Worldwide

Inhibiteur de MAT2A

Solid Tumors
Worldwide
DCP
PRIMARY INDICATION
Solid Tumors
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Solid Tumors
PARTNER
TERRITORY
Worldwide
Solid Tumors
Worldwide

Anti-FLT3

Solid tumors
Worldwide
DCP
PRIMARY INDICATION
Solid tumors
PARTNER
PARTNER
Worldwide
PRIMARY INDICATION
Solid tumors
PARTNER
TERRITORY
Worldwide
Solid tumors
Worldwide

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More